No Data
No Data
GSK Moves to Complete £2 Billion Share Buyback Programme
Sino Biopharm has entered into an exclusive strategic partnership with GlaxoSmithKline to accelerate the launch of bepirovirsen in mainland China.
Gelonghui, May 11th丨Sino Biopharm (01177.HK) announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. ("Chia Tai Tianqing"), has entered into an exclusive strategic partnership with GlaxoSmithKline ("GSK") to accelerate the market launch of bepirovirsen in mainland China. Under the terms of the agreement, Chia Tai Tianqing will be responsible for the importation, distribution, hospital access, as well as promotional and non-promotional activities related to bepirovirsen in mainland China, with all sales revenue generated from this product recognized as part of Chia Tai Tianqing's operating income. GSK will continue to act as the holder of the drug marketing authorization.
GSK Wins Strong Shareholder Backing at 26th Annual General Meeting
Deutsche Bank Sticks to Their Hold Rating for GlaxoSmithKline (GSK)
Citi Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Express News | Citigroup has lowered its target price for GlaxoSmithKline from 2250 pence to 2100 pence.